The adjustment in price target by Canaccord Genuity reflects a slight change in valuation expectations for Rhythm Pharmaceuticals, though the Buy rating indicates continued positive outlook. The minor reduction in price target may have a neutral to slightly negative short-term impact on the stock price, as it suggests a slight adjustment in expectations but not a change in the overall positive sentiment.